Latest Breaking News On - Mastocytosis center - Page 1 : vimarsana.com

Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics

Direct challenges recommended for most antibiotic allergy evaluations

Physicians should perform graded direct challenges when patients at low risk for a reaction report an antibiotic allergy, according to a review published in Annals of Allergy, Asthma & Immunology. In addition to improving clinical outcomes, these challenges often provide cost and time savings compared with skin testing, Allison C. Ramsey, MD, allergy and clinical immunology, Rochester

Blueprint Medicines (BPMC) Announces NEJM Evidence Publishes Results from Registrational PIONEER Trial

NEJM Evidence Publishes Results from Registrational PIONEER Trial Demonstrating Significant Clinical Benefits of AYVAKIT® (avapritinib) in Patients with Indolent Systemic Mastocytosis

/PRNewswire/ Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that NEJM Evidence, a journal from The New England Journal of Medicine Group,.

Blueprint Medicines says its newly approved drug for a rare life-threatening disorder could be a blockbuster

The Cambridge biotech’s treatment combats an immune and blood condition that causes severe allergic reactions to ordinary things, like a whiff of perfume or an elevated heart rate.